BOCOM International Raises AKESO Target Price to HK$183, Maintains "Buy" Rating

Stock News

Aug 28

BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.

The firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a "Buy" rating.

According to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.

The company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1132796683"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132796683\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132796683?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132796683","market":"hk","top_or_hot":-1,"title":"BOCOM International Raises AKESO Target Price to HK$183, Maintains \"Buy\" Rating","media":"Stock News","content":"<p>BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.</p>\n<p>The firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a \"Buy\" rating.</p>\n<p>According to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.</p>\n<p>The company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOCOM International Raises AKESO Target Price to HK$183, Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOCOM International Raises AKESO Target Price to HK$183, Maintains \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-28 17:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.</p>\n<p>The firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a \"Buy\" rating.</p>\n<p>According to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.</p>\n<p>The company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BPRC5H50.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1132796683","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132796683","pubTimestamp":1756374056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","09926":"康方生物","BK1161":"生物科技","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元"},"translate_title":"交银国际上调康方生物目标价至183港元维持“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.\nThe firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a \"Buy\" rating.\nAccording to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.\nThe company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}